Pre-planned Jazz (NASDAQ: JAZZ) director sale of 1,157 shares

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director Mark Douglas Smith reported an open-market sale of 1,157 ordinary shares at $230.55 per share. After this transaction, he directly holds 9,680 ordinary shares. According to a disclosed Rule 10b5-1 trading plan adopted on March 9, 2026, the sale occurred automatically and was not a discretionary trade.

Insider Trade Summary 10b5-1

Net Seller: 1,157 shares ($266,746)

Net Sell 1 txn

Insider Smith Mark Douglas

Role null

Sold 1,157 shs ($267K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	1,157	$230.55	$267K

Holdings After Transaction: Ordinary Shares — 9,680 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 1,157 shares Sale price per share: $230.55 per share Shares held after sale: 9,680 shares +1 more

4 metrics

Shares sold 1,157 shares Ordinary shares sold in open-market transaction

Sale price per share $230.55 per share Price for the 1,157 ordinary shares sold

Shares held after sale 9,680 shares Total direct holdings following the transaction

Net shares sold 1,157 shares Net sell volume in this Form 4

Key Terms

Rule 10b5-1, open-market sale, Securities Exchange Act of 1934

3 terms

Rule 10b5-1 regulatory

"plan adopted by the reporting person on March 9, 2026 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Securities Exchange Act of 1934 regulatory

"in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/17/2026 - 04:45 PM Accepted by SEC EDGAR 06/17/2026 - 04:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Mark Douglas

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/15/2026		S(1)		1,157	D	$230.55	9,680	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a plan adopted by the reporting person on March 9, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

	By: /s/Paz Dizon, as attorney in fact For: Mark D. Smith	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Mark Douglas Smith?

Jazz Pharmaceuticals reported that director Mark Douglas Smith sold 1,157 ordinary shares in an open-market transaction at $230.55 per share. The sale was executed under a pre-established Rule 10b5-1 trading plan and occurred automatically rather than by discretionary choice.

How many Jazz Pharmaceuticals (JAZZ) shares does Mark Douglas Smith hold after the reported sale?

Following the reported transaction, Mark Douglas Smith directly holds 9,680 ordinary shares of Jazz Pharmaceuticals. This post-transaction holding figure is disclosed in the Form 4 and reflects his remaining direct ownership after selling 1,157 shares in the open market.

At what price were the Jazz Pharmaceuticals (JAZZ) shares sold in this Form 4 filing?

The 1,157 ordinary shares were sold at a reported price of $230.55 per share. This price represents the transaction value per share for the open-market sale disclosed and is specifically identified as the sale price in the Form 4 data.

Was the Jazz Pharmaceuticals (JAZZ) insider sale by Mark Douglas Smith discretionary?

The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on March 9, 2026. It notes the transaction occurred automatically and does not represent a discretionary decision by Mark Douglas Smith to sell shares at that particular time.

What does the Rule 10b5-1 plan disclosure mean for this Jazz Pharmaceuticals (JAZZ) trade?

The Rule 10b5-1 disclosure means the trade followed a pre-arranged plan specifying sale conditions in advance. According to the filing, the transaction occurred automatically under this plan, indicating timing was determined by the plan’s terms rather than an ad hoc trading decision.